Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

792
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
792
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

597
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
597
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

718
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
718
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

6.5K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choroidal and Retinal Imaging Findings in Childhood-Onset Mevalonate Kinase Deficiency: An OCT-Based Case-Control Study.

Ocular immunology and inflammation·2026
Same author

A pathogenic CD4 T cell phenotype in experimental uveitis shares common features with other immune mediated inflammatory diseases.

Discovery immunology·2026
Same author

Can NRF2 provide a gene-agnostic approach to treating age-related macular degeneration?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Tissue resident memory T cells populate the human uveal tract.

Scientific reports·2026
Same author

The Immunopathogenesis of uveitis.

Frontiers in medicine·2026
Same author

Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulation.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Related Experiment Video

Updated: Sep 20, 2025

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.4K

Uveitis in Adults: A Review.

Panayiotis Maghsoudlou1,2, Simon J Epps2, Catherine M Guly2

  • 1Academic Unit of Ophthalmology, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

JAMA
|May 28, 2025
PubMed
Summary

Uveitis, an eye inflammation affecting adults aged 20-50, requires prompt treatment to prevent vision loss. Effective therapies include corticosteroids for anterior uveitis and immunosuppressants like adalimumab for refractory posterior uveitis.

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.1K
Puncture-Induced Iris Neovascularization as a Mouse Model of Rubeosis Iridis
06:57

Puncture-Induced Iris Neovascularization as a Mouse Model of Rubeosis Iridis

Published on: March 8, 2018

9.0K

Related Experiment Videos

Last Updated: Sep 20, 2025

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.4K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.1K
Puncture-Induced Iris Neovascularization as a Mouse Model of Rubeosis Iridis
06:57

Puncture-Induced Iris Neovascularization as a Mouse Model of Rubeosis Iridis

Published on: March 8, 2018

9.0K

Area of Science:

  • Ophthalmology
  • Immunology
  • Rheumatology

Background:

  • Uveitis involves inflammation of the eye's uvea, affecting vision and potentially causing severe complications like glaucoma and blindness.
  • It predominantly impacts adults aged 20-50 and can be classified by anatomical location (anterior, intermediate, posterior, panuveitis) and etiology (infectious or noninfectious).
  • Noninfectious uveitis is often associated with systemic conditions like axial spondyloarthritis, while infectious causes include toxoplasmosis, herpes, tuberculosis, and HIV.

Purpose of the Study:

  • To summarize the current understanding of uveitis, including its classification, risk factors, and treatment strategies.
  • To highlight the importance of timely and appropriate management to prevent vision-threatening complications.
  • To review the efficacy of various therapeutic approaches for different uveitis subtypes.

Main Methods:

  • Review of existing literature on uveitis epidemiology, pathogenesis, and clinical management.
  • Analysis of treatment outcomes for different uveitis classifications, including infectious and noninfectious etiologies.
  • Evaluation of first-line and second-line therapies, including corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics.

Main Results:

  • Anterior uveitis typically responds to topical corticosteroids.
  • For posterior noninfectious uveitis, DMARDs like methotrexate and mycophenolate mofetil are effective first-line treatments, achieving remission in a significant percentage of patients.
  • Biologics such as adalimumab demonstrate efficacy as second-line therapy for refractory cases, extending time to treatment failure compared to placebo.

Conclusions:

  • Uveitis management requires a tailored approach based on subtype and etiology.
  • Early intervention with appropriate therapies, including corticosteroids, DMARDs, and biologics, is crucial for preserving vision.
  • Addressing underlying systemic conditions and minimizing corticosteroid side effects are key goals in uveitis treatment.